Insmed Incorporated
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INSM research report →
About the company
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders.
- CEO
- William H. Lewis
- IPO
- 2000
- Employees
- 1,271
- HQ
- Bridgewater, NJ, US
Price Chart
- Market Cap
- $20.42B
- P/E
- -17.15
- P/S
- 24.92
- P/B
- 28.80
- EV/EBITDA
- -18.07
- Div Yield
- 0.00%
- Gross Margin
- 81.56%
- Op Margin
- -137.74%
- Net Margin
- -144.44%
- ROE
- -130.11%
- ROIC
- -65.28%
- Revenue
- $606.42M · 66.73%
- Net Income
- $-1,276,775,000 · -39.73%
- EPS
- $-6.41 · -15.08%
- Op Income
- $-1,176,729,000
- FCF YoY
- -37.09%
- 52W High
- $212.75
- 52W Low
- $70.57
- 50D MA
- $132.30
- 200D MA
- $155.55
- Beta
- 0.77
- Avg Volume
- 2.90M
Get TickerSpark's AI analysis on INSM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 3, 26 | Adsett Roger | sell | 2,370 |
| Jun 3, 26 | Bonstein Sara | sell | 2,404 |
| Jun 3, 26 | Smith Michael Alexander | sell | 2,159 |
| Jun 3, 26 | Lewis William | sell | 7,605 |
| Jun 3, 26 | Flammer Martina M.D. | sell | 2,566 |
| Jun 5, 26 | Flammer Martina M.D. | sell | 1,858 |
| May 22, 26 | Smith Michael Alexander | sell | 6,149 |
| May 18, 26 | Lewis William | other | 4,440 |
| May 18, 26 | Lewis William | other | 6,259 |
| May 18, 26 | Lewis William | sell | 5,753 |
Our INSM coverage
Recent articles, reports, and earnings notes.
Insmed (INSM): BRINSUPRI Launch Drives Premium Growth
Insmed has evolved into a commercial-stage rare respiratory company with two marketed products and a fast-scaling launch. BRINSUPRI is driving the revenue inflection, while ARIKAYCE and a late-stage pipeline add durability and upside.
Insmed Incorporated (INSM) climbs 10.8% on growth outlook
Insmed Incorporated (INSM) climbs sharply as investors continue to digest its strong Q1 update, including rapid BRINSUPRI growth, steady ARIKAYCE sales, and encouraging ENCORE data. The move reflects renewed confidence in the company’s 2026 revenue targets and its expanding commercial and pipeline story.
Want a deeper read on INSM?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.